SGLT2 Inhibitors Have a Breakout Year SGLT2 Inhibitors Have a Breakout Year

First indicated for type 2 diabetes, the benefits proven during the past year have thrust the drug class into the top tier of potential treatments for cardiac and renal disease.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news